ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

KYMR Kymera Therapeutics Inc

37.90
-0.71 (-1.84%)
May 10 2024 - Closed
Delayed by 15 minutes
Company Name Stock Ticker Symbol Market Type
Kymera Therapeutics Inc KYMR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.71 -1.84% 37.90 17:30:00
Open Price Low Price High Price Close Price Prev Close
38.69 37.66 38.93 37.90 38.61
more quote information »

Recent News

Date Time Source Heading
5/08/202407:00GLOBEKymera Therapeutics to Participate in Upcoming May Investor..
5/02/202407:00GLOBEKymera Therapeutics Announces First Quarter 2024 Financial..
4/25/202407:00GLOBEKymera Therapeutics to Report First Quarter 2024 Financial..
4/08/202407:00GLOBEKymera Therapeutics Announces Scientific Presentations at..
3/08/202410:00GLOBEKymera Therapeutics Presents Preclinical Data for STAT6 and..
3/04/202418:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/04/202418:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/04/202418:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/04/202417:50EDGAR2Form 144 - Report of proposed sale of securities
3/04/202417:47EDGAR2Form 144 - Report of proposed sale of securities
2/28/202407:00GLOBEKymera Therapeutics to Participate in Upcoming March..
2/27/202416:22EDGAR2Form 144 - Report of proposed sale of securities
2/22/202407:32EDGAR2Form S-8 - Securities to be offered to employees in employee..
2/22/202407:10EDGAR2Form 8-K - Current report
2/22/202407:00GLOBEKymera Therapeutics Announces Fourth Quarter and Full Year..
2/15/202407:00GLOBEKymera Therapeutics to Report Fourth Quarter and Full Year..
2/09/202419:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/09/202416:22EDGAR2Form 144 - Report of proposed sale of securities
1/31/202407:00GLOBEKymera Therapeutics to Present in Fireside Chat at the..
1/09/202409:17GLOBEKymera Therapeutics Outlines Key 2024 Objectives and..
1/09/202409:15GLOBEKymera Therapeutics Announces Closing of Upsized $275..
1/05/202416:11EDGAR2Form 8-K - Current report
1/05/202416:02EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
1/05/202406:00GLOBEKymera Therapeutics Announces Pricing of $275 Million Public..
1/04/202416:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
1/04/202416:01GLOBEKymera Therapeutics Announces Proposed Public Offering
1/04/202407:08EDGAR2Form 8-K - Current report
1/04/202407:00GLOBER&D Day Highlights Kymera’s Immunology Strategy and Emerging..
1/02/202417:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/02/202407:00GLOBEKymera Therapeutics to Present at the 42nd Annual J.P...
12/13/202307:00GLOBEKymera Therapeutics to Host Virtual Immunology R&D Day on..
12/10/202321:00GLOBEKymera Therapeutics Presents Interim Results from STAT3..
12/07/202307:00GLOBEKymera Therapeutics Announces First Patient Dosed in Phase 2..
11/13/202311:00GLOBEKymera Therapeutics Announces Publication of Phase 1 Trial..
11/06/202318:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/02/202309:15EDGAR2Form 8-K - Current report
11/02/202309:00GLOBEKymera Therapeutics to Present New Clinical Data from the..
11/02/202307:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/02/202307:10EDGAR2Form 8-K - Current report
11/02/202307:00GLOBEKymera Therapeutics Announces Third Quarter 2023 Financial..
11/01/202307:00GLOBEKymera Therapeutics to Participate in Upcoming November..
10/27/202307:00GLOBEKymera Therapeutics Announces First Patient Dosed in Phase 2..
10/26/202307:00GLOBEKymera Therapeutics to Report Third Quarter 2023 Financial..
10/16/202307:00GLOBEKymera Therapeutics Presents Preclinical Data Demonstrating..
9/18/202307:00GLOBEKymera Therapeutics Receives U.S. FDA Fast Track Designation..
8/08/202316:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/03/202307:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/03/202307:10EDGAR2Form 8-K - Current report
8/03/202307:00GLOBEKymera Therapeutics Announces Second Quarter 2023 Financial..
7/27/202307:00GLOBEKymera Therapeutics to Report Second Quarter 2023 Financial..

Your Recent History

Delayed Upgrade Clock